europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Newsletter
    • Library
Become a member
✕

1996: Understanding how the immune system recognises virus-infected cells. Nobel Prize for Physiology or Medicine

02/07/2021

Nominated by: Swiss Biotech Association

Organisations in nomination: Rolf M Zinkernagel, Professor of Experimental Immunology at the University of Zurich   

Viruses infect host cells and reproduce inside them. Immune system killer T-cells destroy those infected cells so that the viruses can’t reproduce.

Professor Zinkernagel, working with Peter Doherty, discovered that in order for killer T-cells to recognize infected cells, they had to recognize two molecules on the surface of the cell, not only the virus antigen, but also a molecule within the major histocompatibility complex (MHC).

This recognition is achieved through a T-cell receptor on the surface of the T-cell.  The MHC had previously been identified as being responsible for the rejection of incompatible tissues during transplantation. Zinkernagel and Doherty discovered that the MHC was also responsible for the body fighting meningitis viruses and were awarded the Nobel Prize for Physiology or Medicine.

The insights from this Nobel-winning discovery, how killer T cells recognise cells to target, have enabled scientists to further investigate how T cells can be used in medical applications, with therapeutics such as CAR-T now presented in immunotherapeutic cancer treatments.

References:

  • Rolf Zinkernagel Nobel Prize in Physiology/Medicine 1996

  • The Nobel Prize in Physiology or Medicine 1996

 

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies